Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus TP chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma
ChiCTR2500111712Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Started Nov 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500111712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111712.